Clinical trial

AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

NCT05302336

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-05-01

PhasePHASE4

Conditions

Breast Cancerverified · MONDO: breast cancer

Chemotherapeutic Toxicityunresolved

Interventions

Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + CyclophosphamideDRUG

Sponsors & collaborators

Second Affiliated Hospital, Zhejiang University, School of Medicinelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05302336 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.